In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Commentary|Podcasts|June 21, 2024
Navigating Market Access Hurdles
Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.
Advertisement
In this exclusive PC Podcast interview, Mark Bouck, chairman and CEO of PharmAlliance, a pharmaceutical and life sciences services platform, dives into:
- How PharmAlliance’s acquisition of Complete Health Economics Outcomes Research Solutions (CHEORS) helps expand global reach
- The platform’s biggest goal to when it comes to CHEORS and market access services
- How CHEORS helps navigate cost-effectiveness and market access hurdles
- Acquisitions in the space that are currently in the works
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
2
Big Three Distributors Lean on Specialty for Profit Growth
3
2026 Brought Progress on Drug Prices. What Will It Take to Improve Patient Access in 2027?
4
The System-Level View That Sound Market Access Decisions Are Missing
5